Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC-HCC Trial: Atezolizumab plus Bevacizumab versus TACE in intermediate-stage hepatocellular carcinoma
KCT0007270Phase 4Not yet recruiting
- Sponsor
- IKF
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of atezolizumab and bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by IKF. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0007270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007270.